The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization

BackgroundPrognostic biomarkers are needed in a heterogeneous population of patients with intermediate hepatocellular carcinoma (HCC) treated by transarterial (chemo)embolization. We aimed to validate the prognostic value of serum CRP levels and the STATE score, combining CRP, albumin and tumor burden.MethodsAll cirrhotic patients with HCC treated by a first transarterial (chemo)embolization (2007–2013) in our institution were included. Overall survival was assessed using the Kaplan–Meier method, log rank, univariate and multivariate Cox analyses.ResultsAmong 157 patients included, 87% were men, 86% had Child Pugh A. Etiologies of liver disease included alcohol (57%), hepatitis C (32%), hepatitis B (11%) and/or metabolic syndrome (32%); 89% of patients were classified BCLC B. 33% of the patients had a CRP >1 mg/dl and 33% a STATE score conferring poor prognosis (<18). Patients with CRP <1 mg/dl had better overall survival than patients with CRP >1 mg/dl (20 vs. 8 months, P = 0.00186). Median overall survival was 6.73 months for patients with a STATE score <18 vs. 22.23 months for patients with STATE-score ≥18 (P = 0.0002). In multivariate analysis, a STATE score <18 was independently associated with increased mortality (HR: 2.06 (CI95%: 1.28–3.34), P = 0.0031).ConclusionIn cirrhotic patients with HCC who underwent transarterial treatment, serum CRP level and STATE score at baseline can predict overall survival.